Novartis AG NVS
145.46
2.75
1.93%
as of 25 Sep
- Market cap
- $264.3B
- P/E
- 21.8×
Follow NVS
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
17.42 | 19.15 | 21.76 | 23.53 |
P/S ratio |
4.38 | 4.72 | 5.15 | 5.27 | |
P/FCF ratio |
14.35 | 17.34 | 18.08 | 19.67 | |
P/Operating CF |
37.59 | 118.08 | 79.33 | 50.76 | |
P/B ratio |
5.52 | 5.74 | 7.49 | 7.12 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
4.74 | 5.10 | 5.83 | 5.96 | |
EV/EBITDA |
11.65 | 12.62 | 14.65 | 14.99 | |
EV/Operating CF |
12.69 | 15.11 | 17.19 | 18.37 | |
EV/FCF |
15.54 | 18.76 | 20.44 | 22.27 | |
Quick Ratio |
0.59 | 0.76 | 0.53 | 0.55 | |
Current Ratio |
0.88 | 1.12 | 0.85 | 0.86 | |
Net Debt/EBITDA |
3.52 | 4.26 | 7.00 | 6.40 | |
Debt/Assets |
28.07% | 30.23% | 38.02% | 38.58% | |
Debt/Equity |
0.67 | 0.72 | 1.16 | 1.12 | |
Asset Turnover |
0.53 | 0.53 | 0.52 | 0.50 | |
Operating CF/Net income |
1.67 | 0.94 | 1.16 | 1.80 | |
Capex/Depreciation |
(0.60) | (0.59) | (0.68) | (0.50) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
20.50% | 22.82% | 20.26% | 19.04% | |
Selling, General and Administrative Expense of Revenue |
23.04% | 24.82% | 23.22% | 21.68% | |
Intangible Assets out of Total Assets |
0.51 | 0.50 | 0.57 | 0.56 | |
Share Based Compensation of Revenue |
1.87% | 2.16% | 2.24% | 1.79% | |
Graham Net Nets |
(0.14) | (0.13) | (0.18) | (0.18) | |
Graham Number |
62.03 | 62.36 | 56.75 | 57.44 | |
Earnings Yield |
5.74% | 5.22% | 4.60% | 4.25% | |
Free Cash Flow Yield |
6.97% | 5.77% | 5.53% | 5.08% | |
Revenue per Share |
7.45 | 7.15 | 7.08 | 7.85 | |
Operating CF per Share |
3.41 | 1.17 | 1.93 | 3.09 | |
Capex per Share |
(0.40) | (0.47) | (0.43) | (0.37) | |
Free Cash Flow per Share |
3.01 | 0.70 | 1.49 | 2.72 | |
Cash per Share |
5.06 | 5.98 | 3.65 | 4.04 | |
Shareholders Equity per Share |
23.24 | 24.01 | 20.39 | 22.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
23.24 | 24.01 | 20.39 | 22.02 | |
Free Cash Flow |
5,793.00 | 1,360.00 | 2,850.00 | 5,174.00 | |
Working Capital |
(3,802.00) | 3,182.00 | (4,767.00) | (4,397.00) | |
Capital Expenditures |
(778.00) | (904.00) | (826.00) | (708.00) | |
Net Current Asset Value |
(34,339.00) | (33,940.00) | (52,998.00) | (52,736.00) | |
EV/EBIT |
15.23 | 16.40 | 19.15 | 19.76 | |
Capex to Sales |
0.05 | 0.07 | 0.06 | 0.05 | |
Net Profit Margin |
27.36% | 17.38% | 23.34% | 21.83% | |
Price to Operating Income |
14.07 | 15.15 | 16.94 | 17.46 | |
| Other line items | |||||
Average Receivables |
8,567.00 | 8,349.00 | 9,163.50 | 9,515.00 | |
Average Payables |
4,321.00 | 4,514.00 | 4,291.50 | 4,382.00 | |
Average Inventory |
6,180.00 | 5,996.00 | 6,057.50 | 6,263.50 | |
Average Assets |
105,406.50 | 106,597.50 | 109,236.50 | 113,214.00 | |
Average Common Equity |
44,096.50 | 45,337.50 | 38,689.50 | 42,000.00 |
Columns are period end dates